Xtant Medical Holdings Inc(XTNT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 5:59 PM ET (Korea 11/3 07:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.08 | Insider Own | 12.43% | Shs Outstand | 140.3M | Perf Week | 1.2% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 60% | Insider Trans | - | Shs Float | 122.9M | Perf Month | -18.38% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.03 | Inst Own | 57.24% | Short Float | 0.24% | Perf Quarter | -36.12% |
| Income | -0.01B | P/S | 0.36 | EPS this Y | -183.33% | Inst Trans | -0.6% | Short Ratio | 0.18 | Perf Half Y | -50.29% |
| Sales | 0.11B | P/B | 0.98 | EPS next 5Y | - | ROA | -12.16% | Short Interest | 0.30M | Perf YTD | -64.49% |
| Book/sh | 0.29 | P/C | 3.82 | EPS past 3/5Y | - | ROE | -25.16% | 52W High | -70.69% ($0.95) | Perf Year | -68.35% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | 32.2% 20.22% | ROIC | -22.41% | 52W Low | 3.03% ($0.27) | Perf 3Y | -76.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -132.84% | Gross Margin | 59.39% | Volatility(W/M) | 8.47% 7.16% | Perf 5Y | -77.37% |
| Dividend TTM | - | EV/Sales | 0.5 | Sales Y/Y TTM | -14.27% | Oper. Margin | -9.58% | ATR (14) | 0.02 | Perf 10Y | -96.24% |
| Dividend Ex-Date | - | Quick Ratio | 1.05 | EPS Q/Q | -380.75% | Profit Margin | -10.17% | RSI (14) | 37.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.16 | Sales Q/Q | -34.96% | SMA20 | -7.6% ($0.3) | Beta | -0.19 | Target Price | $1.03 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/8/11 | SMA50 | -16.04% ($0.33) | Rel Volume | 0.16 | Prev Close | $0.28 |
| Employees | 151 | LT Debt/Eq | 0.24 | EPS/Sales Surpr. | -250% -7.41% | SMA200 | -39.4% ($0.46) | Avg Volume(3M) | 1.67M | Price | $0.28 |
| IPO | 2010/7/1 | Option/Short | No/Yes | Trades | 245 | Volume | 264,948 | Change | -0.64% |
🦴 This is a US medical device company that specializes in developing and manufacturing bone graft materials and biologic agents for spinal surgery. Through its proprietary 'OsteoSelect®' platform and biologics technology, the company is revolutionizing treatment outcomes in orthopedic and spinal surgery.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
XTNT has a sound balance sheet but weak earning power
Of every $100 in sales, $9.58 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -183.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $36. Peers typically go for $145. Compared with its own 2-year average, it is 66653% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -77.4%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 57.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #98 of 140 in the industry
Based on market cap of $39M.
XTNT#98 Xtant Medical Holdings Inc $39M PER - 
CVRX#99 CVRx Inc $36M PER - 
ELUT#100 Elutia Inc $36M PER - 
TELA#101 TELA Bio Inc $36M PER - 
RPID#102 Rapid Micro Biosystems Inc $35M PER - 
FAQ
What kind of company is XTNT?
XTNT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of XTNT?
The market cap of XTNT is approximately $39M, ranking 4,959 within its sector.
What is the 52-week high and low for XTNT?
XTNT has recorded a 52-week high of $0.95 and a low of $0.27.
